Business Context and Reporting Period
This Form 10-Q covers DAXOR CORP for the quarter ended March 31, 1999. The company operates clinical laboratories, including blood and semen banking facilities, and is developing a Blood Volume Analyzer. Operations are currently constrained by ongoing legal disputes with the New York State Department of Health and the New York Blood Center.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $990,329 | $825,525 |
| Operating Revenues | $119,327 | $94,529 |
| Net Income | $313,186 | $(236,455) |
| Net Income Per Share | $0.07 | $(0.05) |
| Cash and Equivalents | $110,237 | $136,131 |
| Marketable Securities (Fair Value) | $37,435,812 | $43,016,243 |
| Total Assets | $38,491,928 | $44,056,349 |
| Total Liabilities | $6,515,674 | $8,752,515 |
| Loans Payable | $1,666,434 | $2,050,549 |
Material Changes
- Profitability Turnaround: The company reported a net income of $313,186, reversing a net loss of $236,455 in the prior year period. This improvement was driven primarily by investment gains rather than core operations.
- Investment Performance: Gains on the sale of securities increased to $403,637 from $235,716. However, the fair value of the marketable securities portfolio declined from $43.0 million to $37.4 million, reducing net unrealized holding gains.
- Expense Reduction: Selling, General, and Administrative expenses dropped significantly to $279,091 from $717,741. Interest expense also decreased to $29,398 from $179,510 due to reduced margin debt.
- Operating Revenue: Core operating revenues grew modestly by approximately 26% to $119,327, though management notes these remain sharply decreased due to legal restrictions on blood and semen banking.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management plans to focus financial reserves on developing and marketing the Blood Volume Analyzer. The company is considering moving semen banking operations out of New York State and discontinuing blood banking operations due to regulatory hostility.
- Legal Contingencies: Significant risks remain regarding a $55 million action in the Court of Claims against the New York State Department of Health and a federal RICO/anti-trust suit against the New York Blood Center. The outcome of these suits is unpredictable.
- Liquidity: The company maintains adequate liquid capital to sustain current operations and marketing efforts. However, a nationwide expansion of blood banking would require additional capital.
- Product Development: The Blood Volume Analyzer is in the process of being introduced to hospitals. The company has agreements for production and fabrication but has not yet generated revenue from this product.
Investor Verification Checklist
- Verify the status and potential settlement value of the $55 million Court of Claims action against the New York State Department of Health.
- Confirm the timeline for FDA clearance and commercial revenue generation for the Blood Volume Analyzer.
- Assess the impact of potential discontinuation of blood and semen banking services on future operating revenue streams.
- Review the composition of the $37.4 million marketable securities portfolio to understand exposure to market volatility.
- Monitor the resolution of the federal RICO/anti-trust suit against the New York Blood Center.